Delaying immune-stimulating drugs after chemotherapy led to fewer cases of severe bone pain, and a two-drug regimen increased progression-free survival in lung cancer.
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and more.
Therapy may reduce a chemotherapy-induced platelet disorder, and PSMA PET scans may help people with suspected prostate cancer forgo a biopsy.
Learn about smoldering myeloma and the first treatment approved by the U.S. Food and Drug Administration to prevent its progression to active multiple myeloma. Circulating throughout our bodies are various types of immune cells...
Treatment regimen approved for multiple myeloma, and people with melanoma who undergo sentinel node biopsy live longer.
Some people with prostate cancer may not need hormone therapy, and colorectal cancer cases shift increasingly to younger adults.
Epidemiologist Elizabeth A. Platz explains what goes into calculating cancer risk estimates, such as rate ratio, hazard ratio, and absolute risk.
First tumor treating fields device for pancreatic cancer approved, and hair extension products often contain potentially dangerous chemicals.
Elizabeth M. Jaffee and Philip D. Greenberg opened AACR IO 2026 with a look at cancer vaccines and the next generation of engineered T cells.
Colorectal cancer cases are becoming more common in younger adults, but there are now more options for screening beyond colonoscopies.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More